Pegvisomant and cabergoline combination therapy in acromegaly

Resistance to Somatostatin Analogs in Acromegaly

(2011) Annamaria Colao et al.   ENDOCRINE REVIEWS

Place of Cabergoline in Acromegaly: A Meta-Analysis

(2011) Laure Sandret et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment

(2010) J. Roemmler et al.   GROWTH HORMONE & IGF RESEARCH

Somatotroph Tumor Progression during Pegvisomant Therapy: A Clinical and Molecular Study

(2010) M. Marazuela et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly

(2009) Philippe Chanson et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

(2009) Peter J. Trainer et al.   CLINICAL ENDOCRINOLOGY

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

(2009) SJCMM Neggers et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy

(2009) Mónica Marazuela et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

ACROSTUDY: the first 5 years

(2009) Peter J Trainer   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues

(2009) M. Sherlock et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

(2009) David J Moore et al.   BMC Endocrine Disorders

Clinical use of cabergoline as primary and adjunctive treatment for acromegaly

(2008) V J Moyes et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

(2008) Camilo Jimenez et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly

(2008) Robert D. Murray et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant

(2008) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Radiotherapy and radiosurgery in acromegaly

(2008) Frédéric Castinetti et al.   Pituitary